Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.55 |
| ▸ | IGF1R | P08069 | 8/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.49 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3442152 | 0.91 | IGF1R (0.57) | SLC2A1MAPK8MAPK9IGF1RMAPK10 | |
| SCHEMBL3442180 | 0.91 | SLC2A1 (0.56) | SLC2A1MAPK8MAPK9IGF1RMAPK10 | |
| SCHEMBL3442177 | 0.91 | SLC2A1 (0.55) | SLC2A1MAPK8MAPK9IGF1RMAPK10 | |
| SCHEMBL3541657 | 0.90 | IGF1R (0.51) | SLC2A1MAPK8MAPK9IGF1RMAPK10 | |
| SCHEMBL3442344 | 0.89 | SLC2A1 (0.72) | SLC2A1MAPK8MAPK9IGF1RMAPK10 | |
| SCHEMBL13118916 | 0.88 | IGF1R (0.56) | SLC2A1MAPK8MAPK9IGF1RMAPK10 | |
| SCHEMBL3541950 | 0.87 | SLC2A1 (0.59) | SLC2A1MAPK8MAPK9IGF1RMAPK10 | |
| SCHEMBL3442091 | 0.86 | SLC2A1 (0.76) | SLC2A1MAPK8MAPK9IGF1RMAPK10 | |
| SCHEMBL3441745 | 0.86 | SLC2A1 (0.64) | SLC2A1MAPK8MAPK9IGF1RMAPK10 | |
| SCHEMBL3537238 | 0.86 | MAPK8 (0.51) | SLC2A1MAPK8MAPK9IGF1RMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971606-B1 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | disclosed |
| EP-1971606-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007067506-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | ERBB2, ERBB3, ERBB4 | SLC2A1 3810/4885MAPK8 263/4885MAPK9 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.